Exchange Traded Concepts LLC Has $145,000 Holdings in Immuneering Co. (NASDAQ:IMRX)

Exchange Traded Concepts LLC decreased its position in Immuneering Co. (NASDAQ:IMRX) by 22.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 58,349 shares of the company’s stock after selling 16,590 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Immuneering were worth $145,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. XTX Topco Ltd increased its stake in Immuneering by 37.3% in the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock valued at $44,000 after buying an additional 9,274 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Immuneering in the 2nd quarter valued at about $44,000. Acadian Asset Management LLC acquired a new stake in shares of Immuneering in the second quarter valued at about $67,000. Vanguard Group Inc. raised its holdings in Immuneering by 12.1% during the first quarter. Vanguard Group Inc. now owns 1,203,666 shares of the company’s stock worth $3,479,000 after acquiring an additional 129,851 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in Immuneering during the second quarter valued at approximately $447,000. 67.65% of the stock is currently owned by institutional investors.

Immuneering Stock Performance

Shares of IMRX opened at $2.20 on Wednesday. The firm has a market cap of $65.24 million, a P/E ratio of -1.18 and a beta of -0.45. Immuneering Co. has a 52 week low of $1.00 and a 52 week high of $8.89. The firm’s 50-day simple moving average is $1.85 and its 200 day simple moving average is $1.59.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Tuesday, August 6th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. As a group, equities analysts forecast that Immuneering Co. will post -1.89 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Chardan Capital cut their price objective on Immuneering from $16.00 to $12.00 and set a “buy” rating for the company in a report on Wednesday, August 7th. Needham & Company LLC restated a “buy” rating and issued a $15.00 price objective on shares of Immuneering in a research note on Friday, September 13th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.60.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.